So-Young shares tumble nearly 8% as Q2 revenue falls short of expectations

So-Young International (NASDAQ:SY) reported a Q2 revenue miss, down 7% YoY to RMB378.7 million, and a non-GAAP net loss, prompting a 7.85% pre-market share decline. Despite the overall contraction, the company's branded aesthetic centers segment surged 426.1% YoY to RMB144.4 million, becoming its largest revenue contributor for the first time and signaling a successful strategic pivot away from declining traditional information and reservation services. This strategic shift is projected to drive significant growth for the aesthetic treatment services segment in Q3, with guidance between RMB150 million and RMB170 million.

Analysis

So-Young International (NASDAQ:SY) reported second-quarter results that highlight a significant strategic transition, triggering a 7.85% pre-market share price decline. The company's total revenue fell 7% year-over-year to RMB378.7 million, and it reported a non-GAAP net loss of RMB30.5 million, a sharp reversal from a RMB22.2 million net income in the prior-year period. This decline was driven by steep contractions in its legacy segments, with information and reservation services revenue falling 35.6% and medical product sales dropping 28.1%. However, the core of the report is the successful pivot to company-owned aesthetic centers; this segment's revenue surged by an explosive 426.1% YoY to RMB144.4 million, becoming the company's largest revenue contributor for the first time. This execution on its transformation strategy is further supported by strong forward guidance, projecting Q3 revenue for this segment to grow between 230.5% and 274.6% YoY. Despite the negative headline figures, the adjusted loss per share of RMB0.05 was narrower than the analyst estimate of a RMB0.18 loss, indicating some underlying operational control amidst the transition.

Key Decisions for Investors

• Investors should evaluate So-Young as a transition-story investment, where the primary thesis rests on the new aesthetic centers segment's ability to grow fast enough to offset the steep, ongoing decline in the legacy business and return the company to positive top-line growth.
• The key metric to monitor in coming quarters will be the revenue mix and the margin profile of the aesthetic centers segment, as its continued expansion must eventually translate into overall company profitability to validate the strategic shift.
• Given the swing to a net loss and the negative market reaction, investors should anticipate continued share price volatility and acknowledge the execution risk associated with scaling a new business model while managing the decline of an old one.